IN2014CN00953A - - Google Patents
Info
- Publication number
- IN2014CN00953A IN2014CN00953A IN953CHN2014A IN2014CN00953A IN 2014CN00953 A IN2014CN00953 A IN 2014CN00953A IN 953CHN2014 A IN953CHN2014 A IN 953CHN2014A IN 2014CN00953 A IN2014CN00953 A IN 2014CN00953A
- Authority
- IN
- India
- Prior art keywords
- influenza
- viruses
- binding molecules
- well
- group
- Prior art date
Links
- 241000712431 Influenza A virus Species 0.000 abstract 2
- 241000713196 Influenza B virus Species 0.000 abstract 2
- 101710154606 Hemagglutinin Proteins 0.000 abstract 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 1
- 101710176177 Protein A56 Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000000185 hemagglutinin Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161572417P | 2011-07-14 | 2011-07-14 | |
| EP11173953 | 2011-07-14 | ||
| PCT/EP2012/063637 WO2013007770A1 (en) | 2011-07-14 | 2012-07-12 | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN00953A true IN2014CN00953A (hr) | 2015-04-10 |
Family
ID=47505543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN953CHN2014 IN2014CN00953A (hr) | 2011-07-14 | 2012-07-12 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8961978B2 (hr) |
| EP (1) | EP2731967B1 (hr) |
| JP (1) | JP5683752B2 (hr) |
| KR (1) | KR101941724B1 (hr) |
| CN (1) | CN103906763B (hr) |
| AU (1) | AU2012282504B2 (hr) |
| BR (1) | BR112014000263B1 (hr) |
| CA (1) | CA2838999C (hr) |
| DK (1) | DK2731967T3 (hr) |
| EA (1) | EA027054B1 (hr) |
| ES (1) | ES2608321T3 (hr) |
| HR (1) | HRP20161740T1 (hr) |
| IL (1) | IL230222A (hr) |
| IN (1) | IN2014CN00953A (hr) |
| MX (1) | MX346206B (hr) |
| MY (1) | MY166282A (hr) |
| WO (1) | WO2013007770A1 (hr) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX346206B (es) | 2011-07-14 | 2017-03-09 | Crucell Holland Bv | Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b. |
| SG11201402633UA (en) | 2011-11-28 | 2014-09-26 | Crucell Holland Bv | Influenza virus vaccines and uses thereof |
| CN104302321A (zh) | 2011-12-05 | 2015-01-21 | 特瑞利斯生物科学有限责任公司 | 可用于被动流感免疫的抗体 |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| US9649375B2 (en) | 2013-03-14 | 2017-05-16 | The Administrators Of The Tulane Educational Fund | Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith |
| WO2014152841A1 (en) | 2013-03-14 | 2014-09-25 | Contrafect Corporation | Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy |
| KR20140118682A (ko) | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물 |
| AU2014273173B2 (en) | 2013-05-30 | 2018-09-27 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| SG11201602522VA (en) * | 2013-10-02 | 2016-04-28 | Medimmune Llc | Neutralizing anti-influenza a antibodies and uses thereof |
| RU2682049C2 (ru) * | 2014-01-27 | 2019-03-14 | Дженентек, Инк. | Лечение вируса гриппа а h7n9 |
| US10639370B2 (en) | 2014-02-04 | 2020-05-05 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
| BR112016018082A2 (pt) * | 2014-02-04 | 2018-02-20 | Contrafect Corporation | ?anticorpos úteis na imunização passiva de influenza e composições, combinações e métodos para uso dos mesmos? |
| CN105992772A (zh) | 2014-02-10 | 2016-10-05 | Igm生命科学股份有限公司 | IgA多特异性结合分子 |
| PE20161376A1 (es) | 2014-03-27 | 2016-12-26 | Genentech Inc | Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso |
| KR101628331B1 (ko) * | 2014-03-28 | 2016-06-08 | 주식회사 녹십자엠에스 | 인플루엔자 a 바이러스 특이적 단클론 항체 및 이를 이용한 인플루엔자 감염 치료 및 진단 방법 |
| KR102461538B1 (ko) | 2014-07-10 | 2022-10-31 | 얀센 백신스 앤드 프리벤션 비.브이. | 인플루엔자 바이러스 백신 및 이의 용도 |
| MX2017000395A (es) | 2014-07-10 | 2018-02-08 | Janssen Vaccines & Prevention Bv | Vacunas contra virus influenza y usos de las mismas. |
| WO2016011035A2 (en) * | 2014-07-15 | 2016-01-21 | Medlmmune, Llc | Neutralizing anti-influenza b antibodies and uses thereof |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| US10174127B2 (en) | 2015-02-05 | 2019-01-08 | Janssen Vaccines & Prevention B.V. | Human neutralizing antibodies binding to influenza neuraminidase |
| BR112017016417A2 (pt) | 2015-02-05 | 2018-03-27 | Janssen Vaccines & Prevention B.V. | moléculas de ligação dirigidas contra hemaglutinina da gripe e seus usos |
| CA2981969C (en) | 2015-04-08 | 2023-12-05 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
| EP3294753A1 (en) | 2015-05-11 | 2018-03-21 | Janssen Vaccines & Prevention B.V. | Influenza virus neutralizing peptidomimetic compounds |
| EP3307310A2 (en) | 2015-05-13 | 2018-04-18 | The Trustees Of The University Of Pennsylvania | Aav-mediated expression of anti-influenza antibodies and methods of use thereof |
| MX2017015189A (es) | 2015-06-01 | 2018-04-13 | Medimmune Llc | Neutralizacion de moleculas de union anti-influenza y usos de las mismas. |
| US10513553B2 (en) | 2015-11-13 | 2019-12-24 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| CN116271017A (zh) | 2016-01-13 | 2023-06-23 | 免疫医疗有限责任公司 | 治疗甲型流感的方法 |
| EP3423484B1 (en) | 2016-03-01 | 2021-01-13 | Janssen Vaccines & Prevention B.V. | Human neutralizing antibodies binding to influenza b neuraminidase |
| WO2017192589A1 (en) * | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| WO2018038096A1 (ja) * | 2016-08-23 | 2018-03-01 | 国立大学法人東京大学 | モノクローナル抗体又はその抗原結合フラグメント及びその使用 |
| EP3532085A1 (en) | 2016-10-27 | 2019-09-04 | Janssen Vaccines & Prevention B.V. | Influenza virus neutralizing compounds |
| EP3574008B1 (en) * | 2017-01-27 | 2023-11-08 | National Research Council of Canada | Hemagglutinin-specific antibodies and uses thereof |
| WO2018141854A1 (en) | 2017-02-02 | 2018-08-09 | Janssen Vaccines & Prevention B.V. | Piperazine derivatives for influenza virus inhibition |
| CA3052353A1 (en) | 2017-02-02 | 2018-08-09 | Janssen Vaccines & Prevention B.V. | Piperazine derivatives for influenza virus inhibition |
| JP7455579B2 (ja) | 2017-02-28 | 2024-03-26 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 新規アデノ随伴ウイルス（ａａｖ）クレードｆベクター及びその用途 |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| CN110573523A (zh) | 2017-02-28 | 2019-12-13 | 宾夕法尼亚州大学信托人 | 基于aav载体的流感疫苗 |
| US11447526B2 (en) | 2018-01-23 | 2022-09-20 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| KR20200115517A (ko) | 2018-01-26 | 2020-10-07 | 리제너론 파마슈티칼스 인코포레이티드 | 인플루엔자 헤마글루티닌에 대한 인간 항체 |
| US11230593B2 (en) | 2019-03-25 | 2022-01-25 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| AU2020342463A1 (en) | 2019-09-05 | 2022-03-24 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| WO2021173965A1 (en) | 2020-02-28 | 2021-09-02 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
| WO2021201677A1 (en) | 2020-04-01 | 2021-10-07 | Kiadis Pharma Intellectual Property B.V. | Compositions and methods targeting influenza |
| US11175293B1 (en) | 2021-01-04 | 2021-11-16 | University Of Utah Research Foundation | Rapid assay for detection of SARS-CoV-2 antibodies |
| EP4289826A1 (en) | 2021-02-04 | 2023-12-13 | Sichuan Haisco Pharmaceutical Co., Ltd. | Salt and crystal form of ha inhibitor compound |
| WO2024104947A2 (en) | 2022-11-14 | 2024-05-23 | Janssen Vaccines & Prevention B.V. | Influenza b virus vaccines and uses thereof |
| CN116589566A (zh) * | 2022-11-18 | 2023-08-15 | 昆明医科大学第一附属医院 | 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| NL9101953A (nl) | 1991-11-21 | 1993-06-16 | Seed Capital Investments | Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen. |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| ATE230850T1 (de) | 1996-10-08 | 2003-01-15 | Bisys B V U | Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül |
| PT1533380E (pt) | 1999-04-15 | 2010-02-09 | Crucell Holland Bv | Produção de proteínas recombinantes numa célula humana compreendendo pelo menos uma proteína e1 de adenovírus |
| US7329530B2 (en) | 2001-06-15 | 2008-02-12 | Crucell Holland B.V. | Chimaeric phages |
| US8192927B2 (en) * | 2006-09-07 | 2012-06-05 | Crucell Holland B.V. | Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| FR2921928B1 (fr) | 2007-10-08 | 2011-03-04 | Sanofi Pasteur | Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal |
| CA2731686C (en) * | 2008-07-25 | 2020-04-07 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| EP2168987A1 (en) * | 2008-09-22 | 2010-03-31 | Mucosis B.V. | Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain |
| AU2010247530B2 (en) | 2009-05-11 | 2016-10-13 | Janssen Vaccines & Prevention B.V. | Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof |
| MX346206B (es) | 2011-07-14 | 2017-03-09 | Crucell Holland Bv | Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b. |
-
2012
- 2012-07-12 MX MX2014000373A patent/MX346206B/es active IP Right Grant
- 2012-07-12 US US14/126,404 patent/US8961978B2/en active Active
- 2012-07-12 KR KR1020137035132A patent/KR101941724B1/ko active IP Right Grant
- 2012-07-12 ES ES12735516.2T patent/ES2608321T3/es active Active
- 2012-07-12 EA EA201490288A patent/EA027054B1/ru not_active IP Right Cessation
- 2012-07-12 IN IN953CHN2014 patent/IN2014CN00953A/en unknown
- 2012-07-12 AU AU2012282504A patent/AU2012282504B2/en active Active
- 2012-07-12 CA CA2838999A patent/CA2838999C/en active Active
- 2012-07-12 EP EP12735516.2A patent/EP2731967B1/en active Active
- 2012-07-12 JP JP2014519551A patent/JP5683752B2/ja active Active
- 2012-07-12 BR BR112014000263-0A patent/BR112014000263B1/pt active IP Right Grant
- 2012-07-12 WO PCT/EP2012/063637 patent/WO2013007770A1/en active Application Filing
- 2012-07-12 DK DK12735516.2T patent/DK2731967T3/en active
- 2012-07-12 MY MYPI2014700068A patent/MY166282A/en unknown
- 2012-07-12 CN CN201280034558.0A patent/CN103906763B/zh active Active
-
2013
- 2013-12-29 IL IL230222A patent/IL230222A/en active IP Right Grant
-
2015
- 2015-01-14 US US14/597,016 patent/US9593159B2/en active Active
-
2016
- 2016-12-19 HR HRP20161740TT patent/HRP20161740T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140120113A1 (en) | 2014-05-01 |
| BR112014000263B1 (pt) | 2022-01-18 |
| HRP20161740T1 (hr) | 2017-02-10 |
| US8961978B2 (en) | 2015-02-24 |
| EA027054B1 (ru) | 2017-06-30 |
| US20150274811A1 (en) | 2015-10-01 |
| AU2012282504B2 (en) | 2017-07-20 |
| EP2731967B1 (en) | 2016-10-12 |
| CN103906763A (zh) | 2014-07-02 |
| CN103906763B (zh) | 2016-10-12 |
| BR112014000263A2 (pt) | 2017-02-14 |
| NZ618530A (en) | 2016-05-27 |
| CA2838999C (en) | 2021-02-16 |
| IL230222A (en) | 2017-09-28 |
| DK2731967T3 (en) | 2017-01-16 |
| MX346206B (es) | 2017-03-09 |
| JP5683752B2 (ja) | 2015-03-11 |
| MY166282A (en) | 2018-06-25 |
| AU2012282504A1 (en) | 2014-02-06 |
| CA2838999A1 (en) | 2013-01-17 |
| MX2014000373A (es) | 2014-03-31 |
| EA201490288A1 (ru) | 2014-05-30 |
| KR20140095017A (ko) | 2014-07-31 |
| KR101941724B1 (ko) | 2019-01-23 |
| US9593159B2 (en) | 2017-03-14 |
| ES2608321T3 (es) | 2017-04-07 |
| EP2731967A1 (en) | 2014-05-21 |
| WO2013007770A1 (en) | 2013-01-17 |
| JP2014527403A (ja) | 2014-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN00953A (hr) | ||
| PH12015502553A1 (en) | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof | |
| MY183517A (en) | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof | |
| GEP20217260B (en) | Antibody neutralizing human respiratory syncytial virus | |
| MY175708A (en) | Dna antibody constructs and method of using same | |
| EA032929B1 (ru) | Нейтрализующее вирус иммунодефицита человека антитело и способы его применения | |
| MX2018000147A (es) | Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45). | |
| MX2014000749A (es) | Anticuerpos neutralizantes del virus de la influenza a y usos de estos. | |
| MX2015005874A (es) | Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos. | |
| EA201490809A1 (ru) | Способы и композиции для лечения неэффективного эритропоэза | |
| BR112014009866A2 (pt) | formulações de anticorpos e métodos | |
| BR112013020500A2 (pt) | anticorpo isolado, recombinante ou purificado | |
| JO3204B1 (ar) | 4- أريل-n- فنيل-5،3،1- ترايازين-2- أمينات محتوية على مجموعة سلفوكسيمين | |
| NZ601793A (en) | Methods and compositions for diagnosis and treatment of cancer | |
| MX2014013678A (es) | Agentes para neutralizacion de influenza. | |
| WO2013020074A3 (en) | A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin | |
| EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| MX2013012233A (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas. | |
| MX2015004389A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionadods. | |
| GB201109238D0 (en) | Antibodies | |
| MX2013001267A (es) | ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD. | |
| EA201590572A1 (ru) | Новые составы, содержащие экстракты растений | |
| TR201910413T4 (tr) | Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler. | |
| MX2013010367A (es) | Composiciones y metodos para la terapia y diagnostico de influenza. | |
| CU20140006A7 (es) | Moléculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenético 1 y grupo filogenético 2 y virus de la influenza b |